---
title: "BIOCAUSE HEILEN PHARMA: Ibuprofen suspension has obtained the drug registration certificate"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/243655036.md"
description: "According to the Zhitong Finance APP, BIOCAUSE HEILEN PHARMA announced that the company recently received the \"Drug Registration Certificate\" approved and issued by the National Medical Products Administration (\"NMPA\"), involving the product: \"Ibuprofen Suspension\". The announcement stated that the registration classification of the ibuprofen suspension is Category 4 chemical drugs, which were reviewed and approved according to the technical requirements consistent with the quality and efficacy of the reference preparation, and after approval, it is deemed to have passed the consistency evaluation of the quality and efficacy of generic drugs"
datetime: "2025-06-09T07:58:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/243655036.md)
  - [en](https://longbridge.com/en/news/243655036.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/243655036.md)
generator: "portal-rs"
---

# BIOCAUSE HEILEN PHARMA: Ibuprofen suspension has obtained the drug registration certificate

According to the Zhitong Finance APP, BIOCAUSE HEILEN PHARMA (301211.SZ) announced that it recently received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration ("NMPA"), involving the product: "Ibuprofen Suspension".

The announcement stated that the registration classification of the Ibuprofen Suspension is a Class 4 chemical drug, which was reviewed and approved according to the technical requirements consistent with the quality and efficacy of the reference preparation, and is deemed to have passed the consistency evaluation of the quality and efficacy of generic drugs after approval

### Related Stocks

- [301211.CN](https://longbridge.com/en/quote/301211.CN.md)

## Related News & Research

- [Livzon Pharma buys 3.5% Xinbeijiang Pharma stake for RMB 106.7 million](https://longbridge.com/en/news/296601614.md)
- [CSPC Innovation Pharmaceutical: Biopharma licensing and product launches drove record revenue and profit growth](https://longbridge.com/en/news/296129143.md)
- [SandboxAQ introduces AQPotency for virtual drug screening](https://longbridge.com/en/news/296467103.md)
- [FONDIA: Profitability improved sharply in H1 2026, driven by growth in Finland and the Baltics](https://longbridge.com/en/news/296439068.md)
- [Butler National Wins Three-Year Extension to Manage Kansas Sports Wagering, Retains 90% Revenue Share](https://longbridge.com/en/news/296516585.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**